In short
Tasipimidine is a new drug being studied for its potential to help people with insomnia disorder. This article discusses recent clinical trials that are testing how well tasipimidine works and how safe it is for patients who have trouble sleeping. We'll look at the study's design, who can participate, and what the researchers hope to learn about this new treatment option.
At a glance
- Drug Name
- Tasipimidine
- Condition Studied
- Insomnia disorder
- Study Design
- Randomized, double-blind, placebo-controlled, dose-escalation, multisite, phase 2a study
- Main Objectives
- Evaluate efficacy, safety, tolerability, and pharmacokinetics of tasipimidine
- Primary Endpoints
- Wake After Sleep Onset (WASO) and Latency to Persistent Sleep (LPS)
- Key Inclusion Criteria
- Age 18-65, diagnosed insomnia disorder, specific sleep difficulties for at least 3 months
- Key Exclusion Criteria
- Sleep-related breathing disorders, unstable psychiatric conditions, significant medical conditions
- Dosage Form
- Oral solution
What is Tasipimidine?
Tasipimidine (also known as ODM-105) is a new medication being studied for the treatment of insomnia disorder. It is currently undergoing clinical trials to evaluate its effectiveness and safety. Tasipimidine is administered as an oral solution, which means it's a liquid that you drink.
Medical Condition Treated
Tasipimidine is being developed to treat insomnia disorder. Insomnia is a sleep disorder characterized by difficulty falling asleep, staying asleep, or both, despite having the opportunity to sleep. This can lead to daytime fatigue, mood disturbances, and impaired performance in daily activities.
How Tasipimidine Works
While the exact mechanism of action is not fully described in the provided information, tasipimidine is likely to work on specific receptors in the brain that are involved in regulating sleep. It's important to note that tasipimidine is a new substance that hasn't been previously authorized for human use, which is why it's undergoing clinical trials.
Clinical Trial Details
The clinical trial for tasipimidine is a Phase IIa study, which means it's in the early stages of testing in humans. Here are some key details about the trial:
- It's a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either tasipimidine or a placebo, and neither the participants nor the researchers know who is receiving which.
- The study is dose-escalating, meaning different groups of participants will receive increasing doses of the medication to determine the most effective and safe dose.
- The study takes place in a sleep laboratory setting, where participants' sleep can be closely monitored.
Eligibility Criteria
To participate in this study, individuals must meet certain criteria. Some key inclusion criteria are:
- Age between 18 and 65 years.
- Diagnosed with insomnia disorder according to DSM-5-TR® criteria.
- History of taking 30 minutes or more to fall asleep and sleeping 6 hours or less, at least 3 nights per week for at least 3 months.
- An Insomnia Severity Index© (ISI©) score of 15 or higher. This is a clinical tool used to measure the severity of insomnia symptoms.
There are also several exclusion criteria, such as certain medical conditions or use of specific medications, that would prevent someone from participating in the study.
Potential Benefits
The main goals of the tasipimidine study are to evaluate its effectiveness in treating insomnia. Specifically, the researchers are looking at:
- Wake after sleep onset (WASO): This measures how much time a person spends awake after initially falling asleep.
- Latency to persistent sleep (LPS): This measures how long it takes a person to fall into a steady state of sleep.
If successful, tasipimidine could potentially help people with insomnia fall asleep faster and stay asleep longer.
Safety Considerations
As with any new medication, safety is a primary concern. The study is closely monitoring several safety aspects, including:
- Adverse events (side effects)
- Blood pressure changes
- Morning sleepiness
- Changes in laboratory tests
It's important to note that as tasipimidine is still in the early stages of testing, not all potential side effects may be known. The study is designed to carefully monitor participants and gather this important safety information.